Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Agents: Other Topics

Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts

Emily Rodela, Pawan Noel, Shaimaa Hussein, Yin C. Lin, Daniel D. Von Hoff and Haiyong Han
Emily Rodela
1Translational Genomics Research Institute (TGen), Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pawan Noel
2TGen (The Translational Genomics Research Institute), Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaimaa Hussein
3Baylor Institute for Immunology Research, Dallas, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin C. Lin
3Baylor Institute for Immunology Research, Dallas, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel D. Von Hoff
2TGen (The Translational Genomics Research Institute), Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiyong Han
1Translational Genomics Research Institute (TGen), Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-17-LB-B27 Published January 2018
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA

Abstract

GZ17-6.02 is a synthetic formulation of Arum palaestinum extracts that has shown significant antitumor activity against a variety of cancer types including pancreatic ductal adenocarcinoma (PDAC). Previous studies have showed that GZ17-6.02 significantly inhibited PDAC tumor growth in an orthotopic xenograft mouse model for PDAC. Mechanistically, GZ17-6.02 suppressed the expression of multiple tumor stem cell markers in PDAC cells. However, the exact mechanism of action or cellular targets of GZ17-6.02 is not well understood. Considering the substantial effect of GZ17-6.02 on transcription, we hypothesized that GZ17-6.02 might affect the super-enhancers (SEs) networks in pancreatic cancer cells and/or stromal fibroblasts. In this study, we sought to evaluate the effect of GZ17-6.02 on global gene expression, particularly those associated with super-enhancers in PDAC cells and cancer associated fibroblasts (CAFs) using whole genome RNA sequencing (RNA-Seq) and chromatin immunoprecipitation sequencing (ChIP-Seq) assays. Our results showed that GZ17-6.02 induced expression changes in a large number of genes in both pancreatic cancer cells and CAFs. Overall, GZ17-6.02 induced expression changes in more genes in the cancer cells (MIA PaCa-2) than in the CAFs (CAF08). Clustering analysis showed that the top differentially expressed genes are very different between the cancer and CAF cells. In MIA PaCa-2 cells, GZ17-6.02 most significantly affected pathways related to gap junctions whereas in CAF08 cells, pathways related to extracellular matrix proteins such as hyaluronan were among the most significantly dysregulated by the drug. The ChIP-seq results indicated that GZ17-6.02 treatment at 50 μg/mL for 6 hours disrupted many SEs, which may have caused changes in the expression of genes associated with those SEs in the pancreatic cancer cells. The effect of GZ17-6.02 at 50 μg/mL for 6 hours on SEs in the CAF08 was not significant. This is consistent with the fact that relatively small effect on global gene expression in CAF08 cells was observed in the transcriptome analysis. Overall, our study demonstrates that GZ17-6.02 exerts discrete effects on pancreatic cancer cells and CAFs, indicating that the drug may target both the tumors and their associated fibroblasts (stroma). Furthermore, GZ17-6.02 may disrupt super-enhancer networks in the tumor cells to affect genes that play important roles in pancreatic cancer.

Citation Format: Emily Rodela, Pawan Noel, Shaimaa Hussein, Yin C. Lin, Daniel D. Von Hoff, Haiyong Han. Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B27.

  • ©2018 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 17 (1 Supplement)
January 2018
Volume 17, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts
Emily Rodela, Pawan Noel, Shaimaa Hussein, Yin C. Lin, Daniel D. Von Hoff and Haiyong Han
Mol Cancer Ther January 1 2018 (17) (1 Supplement) LB-B27; DOI: 10.1158/1535-7163.TARG-17-LB-B27

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts
Emily Rodela, Pawan Noel, Shaimaa Hussein, Yin C. Lin, Daniel D. Von Hoff and Haiyong Han
Mol Cancer Ther January 1 2018 (17) (1 Supplement) LB-B27; DOI: 10.1158/1535-7163.TARG-17-LB-B27
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Therapeutic Agents: Other Topics

  • Abstract B138: Prognostic value of PTEN loss for second-line paclitaxel treatment efficacy in metastatic gastric cancer
  • Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP
  • Abstract B141: Repurposing of ketorolac for the treatment of renal cell carcinoma (RCC)
Show more Therapeutic Agents: Other Topics

Therapeutic Agents: Other Topics: Poster Presentations - Proffered Abstracts

  • Abstract B138: Prognostic value of PTEN loss for second-line paclitaxel treatment efficacy in metastatic gastric cancer
  • Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP
  • Abstract B141: Repurposing of ketorolac for the treatment of renal cell carcinoma (RCC)
Show more Therapeutic Agents: Other Topics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement